Ciprofloxacin-resistant Salmonella typhi and treatment failure

Ciprofloxacin is suggested as an alternative to chloramphenicol for the treatment of typhoid fever in patients in the UK recently returned from countries in the Indian sub-continent, but there are alternatives when strains become drug-resistant.

Saved in:
Bibliographic Details
Published inThe Lancet (British edition) Vol. 353; no. 9164; pp. 1590 - 1591
Main Authors Threlfall, EJ, Ward, LR, Skinner, JA, Smith, HR, Lacey, S
Format Journal Article
LanguageEnglish
Published London Elsevier Ltd 08.05.1999
Lancet
Elsevier Limited
Subjects
Aged
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Bacterial diseases
Biological and medical sciences
Ciprofloxacin - metabolism
Ciprofloxacin - therapeutic use
Drug resistance
Drug Resistance, Microbial
Drug therapy
Female
Human bacterial diseases
Humans
Infant
Infectious diseases
Medical research
Medical sciences
Miscellaneous
Pharmacology. Drug treatments
Salmonella
Salmonella typhi - drug effects
Treatment Failure
Tropical bacterial diseases
Typhoid
Typhoid Fever - drug therapy
Waterborne diseases
Asia
United Kingdom > UK
India
Human
Quinoline derivatives
Typhoid
Bacteriological investigation
Recommendation
Infection
Antibiotic
Chemotherapy
Fluoroquinolone derivatives
Imported disease
Treatment
Nalidixic acid
Bacteriosis
Salmonellosis
Antibacterial agent
Ciprofloxacin
Negative therapeutic reaction
Quinolone derivatives
Online AccessGet full text

Cover

More Information
Summary:Ciprofloxacin is suggested as an alternative to chloramphenicol for the treatment of typhoid fever in patients in the UK recently returned from countries in the Indian sub-continent, but there are alternatives when strains become drug-resistant.
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 23
ObjectType-Review-2
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(99)01001-6